ascopubs.org4d
Acquired gene alterations potentially related to resistance to anti-HER2 therapy in HER2-positive metastatic colorectal cancer (mCRC).
This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full text component.
Morningstar7d
EXUMA Biotech Announces Phase 1 Results for its Autologous HER2 Directed, Tumor Metabolism Regulated (TMR) CAR-T Product at ASCO GI 2025
is presenting clinical data from a completed Phase 1 trial evaluating a novel autologous HER2-targeted CAR-T therapy. The data presented today at the ASCO Gastrointestinal Cancers Symposium ...
Enhertu approved in the US as HER2-directed therapy
AstraZeneca (AZN) and Daiichi Sankyo’s ENHERTU has been approved in the US for the treatment of adult patients with unresectable or metastatic ...
Nasdaq7d
ALX Oncology Presents Positive Evorpacept Data at 2025 ASCO Gastrointestinal Cancers Symposium, Highlighting Strong Efficacy in HER2-Positive Cancer
at the 2025 ASCO Gastrointestinal Cancers Symposium. This investigational treatment demonstrated significant tumor response and a favorable safety profile, particularly in patients with HER2 ...
Business Insider9d
ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI
Webcast on January 23 at 1:00 p.m. PT/4:00 p.m. ET will review updated data from trial evaluating CD47-blocker evorpacept in HER2-positive ... Cancers Symposium (ASCO GI) earlier the same day.